A new class III hepatitis B drug is a recombinant cytokine gene-derived protein injection. Generation 1-2 therapeutic drugs for chronic hepatitis B are nucleoside analogs and interferon drugs. Nucleoside analogs can be further categorized into the nucleoside analogs lamivudine and entecavir, and the nucleotide analogs adefovir and tenofovir. Interferons such as long-acting interferon, polyethylene glycolized interferon, etc. The third category of new hepatitis B drugs is commonly recombinant cytokine gene-derived protein injections. It belongs to the “immunotherapy” drugs, can be based on the molecular structure of the regulatory protein amino acid sequence system modification, through more efficient regulation and enhancement of immune function, showing the effect of the treatment of viral diseases, malignant tumors and autoimmune diseases. The third class of new hepatitis B drugs also have certain side effects, common headache, nausea, loss of appetite, fever and other adverse reactions. It is contraindicated for those who are allergic to the drug. Since the clinical data of the third category of new hepatitis B drugs is not rich enough, it is still subject to further clinical observation, and whether it can be applied to all patients needs to be further evaluated by clinical experts.